Navigation Links
UCLA researchers discover a potential target for therapy for patients with a deadly prostate cancer
Date:11/8/2010

A monoclonal antibody targeting a well known cell surface protein inhibited prostate cancer growth and metastasis in an aggressive form of the disease that did not respond to hormone therapy, according to a study by researchers with the UCLA Department of Urology and UCLA's Jonsson Comprehensive Cancer Center.

The researchers also found that the protein, N-cadherin, is up regulated or turned on in prostate cancer that does not respond to hormone therapy, known as castration resistant disease. The results of the study, done in cell lines and mouse models, were confirmed in humans after researchers examined tissue from dozens of men who died from prostate cancer, said Dr. Robert Reiter, a professor of urology, a Jonsson Cancer Center scientist and senior author of the study.

"This therapy may be particularly useful in men who are failing the newest forms of treatment that target the androgen receptor, which regulates testosterone," said Reiter, who is director of the cancer center's Specialized Program of Research Excellence (SPORE) in prostate cancer. "This could potentially offer an effective alternative or addition to those hormone therapies."

The study appears Nov. 7, 2010 in the early online edition of the peer-reviewed journal Nature Medicine.

The study represents a translational effort by Reiter and his team to take their basic science observations and transform them into new therapies for this aggressive form of prostate cancer to be tested in clinical trials. Observations made in those future clinical trials also could be used in the laboratory to refine potential therapies.

Reiter and his team first found that the N-cadherin gene was up regulated in castration resistant prostate cancer, presenting a potential target for therapy. The findings in cell lines and mouse models were confirmed by studying tissue from men who died from their castration resistant disease. Researchers then found that the up regulation is required to maintain castration resistant prostate cancers, meaning that the turning on of the pathway may be a cause of the hormone therapy resistance, making it an even more attractive target for therapy.

Armed with a hypothetical target at which to aim molecular therapies, Reiter and his team set out to develop novel therapeutics to block N-cadherin. They developed two monoclonal antibodies to test on their cell lines and animal models and found that the antibodies slowed the growth in their prostate cancer cell lines and mouse models and blocked the spread of castration resistant prostate cancer in mouse models. Reiter said this finding may mean the antibodies could potentially be used to block the spread of prostate cancer in men diagnosed with this aggressive form of the castration resistant disease, making it easier to treat and potentially improving outcomes in this patient population. It could also be effective in preventing men treated for early stage disease from progressing to castration resistance since the antibodies prevented that progression in the cell lines and mouse models, Reiter said.

"We believe these findings show that the up regulation of N-cadherin is one of the mechanisms that leads to castration resistance and it could be targeted perhaps in conjunction with other pathways already being studied that lead to resistance," Reiter said. "These findings may provide us with yet another way to treat these cancers."

Although many men have indolent or slow growing prostate cancers that often are only observed over time, a significant percent of patients present with castration resistant disease or later develop castration resistance, which is very difficult to treat effectively. It would be very useful to have another tool in the arsenal to fight this type of prostate cancer, Reiter said.

The next step for Reiter and his team is to improve the antibodies and understand the mechanism by which N-cadherin works to promote resistance. Human clinical trials testing the antibodies would be opened in the future.

Reiter said his findings were somewhat surprising.

"We didn't think we'd see the level of activity that we did," he said. "And we didn't think the antibodies would block castration resistance."


'/>"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
Source:Eurekalert

Related biology news :

1. NC State researchers get to root of parasite genome
2. Researchers find animal with ability to survive climate change
3. Researchers find an essential gene for forming ears of corn
4. Researchers note differences between people and animals on calorie restriction
5. Researchers study acoustic communication in deep-sea fish
6. Researchers discover that growing up too fast may mean dying young in honey bees
7. Researchers study how pistachios may improve heart health
8. UI researchers find potentially toxic substance present in Chicago air
9. Researchers develop new self-training gene prediction program for fungi
10. Case Western Reserve University researchers track Chernobyl fallout
11. Childrens National researchers develop novel anti-tumor vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2016)... England and DE SOTO, Kansas ... , U.S.-based Stroke Detection Plus® to offer Oncimmune,s ... risk assessment and early detection of lung cancer ... large employers, unions and individuals. --> Early ... unions and individuals. --> Oncimmune, a leader ...
(Date:3/2/2016)... March 2, 2016 ... the "Global Biometrics as a Service ... --> http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has ... Biometrics as a Service Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) ...
(Date:3/1/2016)... , March 1, 2016  (RSAC Booth #3041) – ... a whopping $118 billion is lost to false positives, ... and inaccurate fraud detection. At the RSA Conference 2016, ... way companies handle authentication by devaluing the data fraudsters ... analytics. --> --> ...
Breaking Biology News(10 mins):
(Date:4/28/2016)... , April 28, 2016 The ... and Brayton Cryocoolers), Service (Technical Support, Product Repairs & ... - Global Forecast to 2022", published by MarketsandMarkets, the ... Billion by 2022, at a CAGR of 7.29% between ... data Tables and 94 Figures spread through 159 Pages ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... hold an open house for regional manufacturers at its Maple Grove, Minnesota technical ... Okuma, Hardinge Group, Chiron and Trumpf. Almost 20 leading suppliers of tooling, ...
(Date:4/27/2016)... 2016 NanoStruck Technologies Inc. ... ( Frankfurt : 8NSK) gibt bekannt, ... 13. August 2015 die Genehmigung von der CNSX ... 200.000.000 Einheiten auf 400.000.000 Einheiten zu erhöhen, um ... wurden 157.900.000 Einheiten mit dem ersten Teil der ...
(Date:4/27/2016)... ... April 27, 2016 , ... A compact PET ... Tomography) and MRI (Magnetic Resonance Imaging) in existing third-party MRI systems. PET and ... in small animal subjects. Simultaneous PET/MRI imaging offers a solution to many challenges ...
Breaking Biology Technology: